Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PPBT Stock Forecast 2026-2027
$1.58
Current Price
$1.47M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PPBT Price Targets
+1,798.7%
To High Target of $30.00
+1,798.7%
To Median Target of $30.00
+1,798.7%
To Low Target of $30.00
PPBT Price Momentum
-46.8%
1 Week Change
-57.2%
1 Month Change
-93.6%
1 Year Change
-76.0%
Year-to-Date Change
-94.6%
From 52W High of $29.00
+11.3%
From 52W Low of $1.42
📊 TOP ANALYST CALLS
Did PPBT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Purple Biotech is one of their latest high-conviction picks.
Latest PPBT Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, PPBT has a bullish consensus with a median price target of $30.00 (ranging from $30.00 to $30.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.58, the median forecast implies a 1,798.7% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Emily Bodnar at HC Wainwright & Co., projecting a 1,798.7% upside. Conversely, the most conservative target is provided by Emily Bodnar at HC Wainwright & Co., suggesting a 1,798.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PPBT Analyst Ratings
1
Buy
0
Hold
0
Sell
PPBT Price Target Range
Low
$30.00
Average
$30.00
High
$30.00
Current: $1.58
Latest PPBT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PPBT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2026 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $30.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 20, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 19, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jul 11, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 21, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 26, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 7, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 5, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 27, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 21, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 31, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 30, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jul 21, 2023 | JonesTrading | Buy | Initiates | $N/A | |
| May 17, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 17, 2023 | Chardan Capital | Buy | Reiterates | $N/A | |
| Feb 9, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 9, 2023 | Chardan Capital | Buy | Reiterates | $N/A | |
| Oct 17, 2022 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Sep 8, 2022 | Chardan Capital | Buy | Initiates | $N/A |
Purple Biotech Ltd. (PPBT) Competitors
The following stocks are similar to Purple Biotech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Purple Biotech Ltd. (PPBT) Financial Data
Purple Biotech Ltd. has a market capitalization of $1.47M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -123.3%.
Valuation Metrics
Market Cap
$1.47M
Enterprise Value
$-4,829,530
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+437.0%
Current Ratio
1.5x
Debt/Equity
1.9x
ROE
-123.3%
ROA
-19.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Purple Biotech Ltd. (PPBT) Business Model
About Purple Biotech Ltd.
What They Do
Develops novel cancer therapies.
Business Model
The company advances drug candidates through clinical trials, generating revenue by optimizing innovative solutions for unmet medical needs in oncology. Their focus on targeting the tumor microenvironment allows them to develop therapies across various cancer types, potentially increasing their market reach and impact.
Additional Information
Headquartered in Israel, Purple Biotech emphasizes innovative research, particularly in inhibiting energy supply to cancer cells. Their lead candidates are at various developmental stages, showcasing a commitment to scientific advancement and enhancing patient outcomes in cancer treatment.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
9
CEO
Mr. Gil Efron CPA, M.A.
Country
Israel
IPO Year
2015
Website
purple-biotech.comPurple Biotech Ltd. (PPBT) Latest News & Analysis
Latest News
Purple Biotech Announces CEO Transition
3 months ago
Quick Summary
Gil Efron will resign as CEO in August 2026 due to health reasons but will remain involved in corporate development.
Why It Matters
Leadership changes can impact company strategy and performance. Efron's ongoing role in corporate development may ensure stability during the transition, but health concerns could affect investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Purple Biotech Ltd. will change its ADS ratio from 1 ADS for 200 ordinary shares to 1 ADS for 2,000 ordinary shares, effective March 2, 2026.
Why It Matters
The ADS ratio change indicates a potential dilution of shares, affecting liquidity and investor perception. It may influence trading volume and valuation of Purple Biotech's ADS.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Purple Biotech will present new preclinical data on its CAPTN-3 platform, focusing on anti-tumor activity in treatment-resistant cancers, at the ESMO-IO 2025 Congress from December 10-12.
Why It Matters
New data on Purple Biotech's CAPTN-3 platform highlights its potential to treat resistant cancers, which could enhance its market position and attract investor interest ahead of the ESMO-IO congress.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
6 months ago
Quick Summary
Purple Biotech initiated development of a second CAPTN-3 tri-specific antibody and achieved a manufacturing milestone for IM1240. The company reported a cash position of $10.5 million as of September 30, 2025.
Why It Matters
Purple Biotech's development of new tri-specific antibodies and solid cash position signal ongoing innovation and financial stability, crucial for potential growth and investor confidence in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
7 months ago
Quick Summary
Purple Biotech achieved a manufacturing milestone for IM1240, a tri-specific antibody targeting the 5T4 antigen, and plans to submit an IND for first-in-human trials in 2026.
Why It Matters
The achievement of a commercially viable yield for IM1240 and progress towards clinical trials enhances Purple Biotech's competitive position and potential for significant future revenue, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) received a notice from Nasdaq for non-compliance with the minimum bid price requirement, as its ADSs have traded below $1.00 for 30 consecutive days.
Why It Matters
Purple Biotech's non-compliance with Nasdaq's minimum bid price could lead to delisting, impacting its stock liquidity and investor confidence, potentially driving down share value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PPBT Stock
What is Purple Biotech Ltd.'s (PPBT) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Purple Biotech Ltd. (PPBT) has a median price target of $30.00. The highest price target is $30.00 and the lowest is $30.00.
Is PPBT stock a good investment in 2026?
According to current analyst ratings, PPBT has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.58. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PPBT stock?
Wall Street analysts predict PPBT stock could reach $30.00 in the next 12 months. This represents a 1,798.7% increase from the current price of $1.58. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Purple Biotech Ltd.'s business model?
The company advances drug candidates through clinical trials, generating revenue by optimizing innovative solutions for unmet medical needs in oncology. Their focus on targeting the tumor microenvironment allows them to develop therapies across various cancer types, potentially increasing their market reach and impact.
What is the highest forecasted price for PPBT Purple Biotech Ltd.?
The highest price target for PPBT is $30.00 from Emily Bodnar at HC Wainwright & Co., which represents a 1,798.7% increase from the current price of $1.58.
What is the lowest forecasted price for PPBT Purple Biotech Ltd.?
The lowest price target for PPBT is $30.00 from Emily Bodnar at HC Wainwright & Co., which represents a 1,798.7% increase from the current price of $1.58.
What is the overall PPBT consensus from analysts for Purple Biotech Ltd.?
The overall analyst consensus for PPBT is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are PPBT stock price projections?
Stock price projections, including those for Purple Biotech Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 2:00 AM UTC